Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 230

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer

Open access
Nagaraja, Ankur K., Creighton, Chad J., Yu, Zhifeng, Zhu, Huifeng, Gunaratne, Preethi H., Reid, Jeffrey G., Olokpa, Emuejevoke, Itamochi, Hiroaki, Ueno, Naoto T., Hawkins, Shannon M., Anderson, Matthew L., Matzuk, Martin M.·2010·Molecular Endocrinology

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs that direct gene regulation through translational repression and degradation of complementary mRNA. Although miRNAs have been implicated as oncogenes and tumor suppressors in a variety of human cancers, functional roles for individual miRNAs have not been described in clear cell ovarian carcinoma, an aggressive and chemoresistant subtype of ovarian cancer. We performed deep sequencing to comprehensively profile miRNA expression in 10 human clear cell ovarian cancer cell lines compared with normal ovarian surface epithelial cultures and discovered 54 miRNAs that were aberrantly expressed. Because of the critical roles of the phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog 1/mammalian target of rapamycin (mTOR) pathway in clear cell ovarian cancer, we focused on mir-100, a putative tumor suppressor that was the most down-regulated miRNA in our cancer cell lines, and its up-regulated target, FRAP1/mTOR. Overexpression of mir-100 inhibited mTOR signaling and enhanced sensitivity to the rapamycin analog RAD001 (everolimus), confirming the key relationship between mir-100 and the mTOR pathway. Furthermore, overexpression of the putative tumor suppressor mir-22 repressed the EVI1 oncogene, which is known to suppress apoptosis by stimulating phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog 1 signaling. In addition to these specific effects, reversing the expression of mir-22 and the putative oncogene mir-182 had widespread effects on target and nontarget gene populations that ultimately caused a global shift in the cancer gene signature toward a more normal state. Our experiments have revealed strong candidate miRNAs and their target genes that may contribute to the pathogenesis of clear cell ovarian cancer, thereby highlighting alternative therapeutic strategies for the treatment of this deadly cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/me.2009-0295

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 230

Metadata

Authors
Nagaraja, A. K., Creighton, C. J., Yu, Z., Zhu, H., Gunaratne, P. H., Reid, J. G., Olokpa, E., Itamochi, H., Ueno, N. T., Hawkins, S. M., Anderson, M. L., & Matzuk, M. M.
Venue
Molecular Endocrinology
Published
2010-02-01
Volume
24
Issue
2
Pages
447-463
ISSN
  • 0888-8809 (ISSN-L)
  • 1944-9917
OpenAlex
W2005479935
Cited by
230
References
6
FWCI
8.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer. https://app.cochat.ai/papers/10.1210/me.2009-0295
The paper
Nagaraja, A. K., Creighton, C. J., Yu, Z., Zhu, H., Gunaratne, P. H., Reid, J. G., Olokpa, E., Itamochi, H., Ueno, N. T., Hawkins, S. M., Anderson, M. L., & Matzuk, M. M. (2010). A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer. Molecular Endocrinology. https://doi.org/10.1210/me.2009-0295

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.